Drugs / HLX05
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06980454 | Jun → Dec 2025 overdue | colorectal cancer | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06309043 | Apr 2024 → Jun 2026 overdue | — | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX05 | “HLX05 Vs. Erbitux® (Cetuximab)” NCT06309043 ↗ |
| Action | Inhibit | “anti-EGFR” NCT06309043 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT06309043 ↗ |
| Route | Intravenous | “single intravenous dose” NCT06309043 ↗ |
| Target | EGFR | “anti-EGFR” NCT06309043 ↗ |